524 Background: Lenvatinib (LEN) is approved for first-line treatment of uHCC. Baseline
(BL) liver function (Child-Pugh score [CPS] and albumin-bilirubin grade [ALBI]) was …

TO THE EDITOR: The article by Beumer et al 1 addressed the effect of renal impairment on
the toxicity of anticancer compounds tested in phase I trials over three decades, and the …

TO THE EDITOR: Cainap et al 1 reported results of a randomized, open-label phase III trial
evaluating linifanib versus sorafenib in patients with advanced hepatocellular carcinoma …

3538 Background: We sought to characterize the PK and determine a tolerable dose of S in
patients with HD or RD. Methods: Patients with performance status 0–2 and pathologically …

Sorafenib and cisplatin plus gemcitabine currently represent first-line treatment standards in
advanced hepatocellular carcinoma and biliary cancer, respectively. Conventional cytotoxic …

The population of patients with hepatocellular carcinoma (HCC) overlaps to a high degree
with those for chronic kidney disease (CKD) and end-stage renal disease (ESRD). The …

Purpose To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in
patients with liver dysfunction (LD). Patients and Methods Patients (N= 89) with varying solid …

Although clinical trials for drug approval are conducted in patients with normal renal
function, cancer patients in clinical practice may have compromised renal function because …

Few epidemiologic studies describe longitudinal liver chemistry (LC) elevations in cancer
patients. A population-based retrospective cohort was identified from 31 Phase 2–3 …

Highlights•Most common types of drug-induced liver injuries in oncology are presented.•
Hepatotoxicity of chemotherapy and molecular targeted therapies is reviewed.•Imaging …